Several of the biggest US pharmacy benefit managers have generated more than $7.3bn in revenue by charging “enormous mark-ups” for drugs treating cancer and HIV, according to the US Federal Trade Commission.
A report published by the competition regulator on Tuesday named CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth Group’s Optum, which administer about 80 per cent of all prescriptions in the US.
Pharmacy benefit managers, or PBMs, act as middlemen within the pharmaceutical industry. They negotiate rebates from wholesale prices with drugmakers, before passing some of the discount on to consumers and pocketing the rest as profits.
您已阅读22%（654字），剩余78%（2324字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。
成为付费会员，阅读FT独家内容
如您已经是会员，